Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com. SOURCE UCB, Inc. -- UCB-sponsored data include the first presentation of investigational data of VIMPAT (lacosamide) as monotherapy for the treatment of partial-onset seizures in adults with epilepsy ATLANTA, Nov. 20, 2013 /PRNewswire/ -- UCB, a global biopharmaceutical company focusing on CNS and immunology treatment and research, will be sponsoring 15 data presentations at the 67th Annual Meeting of the American Epilepsy Society in Washington, D.C., December 610. The poster presentations on VIMPAT (lacosamide) C-V include investigational data evaluating VIMPAT as monotherapy and further studies of VIMPAT as add-on therapy for the treatment of partial-onset seizures in adults with epilepsy. VIMPAT is indicated as an adjunctive therapy for the treatment of partial-onset seizures in adults with epilepsy (ages >/= 17 in the U.S., ages >/= 16 years in the EU).1,2 The most common adverse reactions reported in pivotal trials and occurring in 10 percent or more of VIMPAT-treated patients, and greater than placebo, were dizziness, headache, nausea, and diplopia. Lacosamide is not … Continue reading →

Posted January 22, 2014 Pat Skerrys experiences with his son, Owen, have inspired his autism outreach efforts. (Mitchell Layton/Getty) On Monday night, Pat Skerry was babysitting. Which is to say he actually was parenting, though the difference can be blurred amusingly by the harried existence of a college basketball coach. Anyway, it was closing in on 7 p.m. when Skerrys son, Owen, was working the iPad and in particular a specific app his mother installed to help him understand words and communicate. Owen, nearing his fifth birthday, is autistic. His vocabulary and language skills are limited. His intuition is not. Which was how Owen calculated the time of day and tapped into his sense of routine before tapping into technology to issue a pronouncement to a somewhat preoccupied dad. I want to take a bath, Pat Skerry was informed. Hes an unbelievable wizard on the iPad and some of these electronic gadgets, Skerry, the Towson basketball coach, said in a phone conversation Tuesday morning. Hes a heck of a lot smarter than I am with that stuff. If Skerry cant quite use a touch-screen as adeptly, he can use his position and his platform to advance awareness of the condition … Continue reading →

Posted January 22, 2014 Pat Skerrys experiences with his son, Owen, have inspired his autism outreach efforts. (Mitchell Layton/Getty) On Monday night, Pat Skerry was babysitting. Which is to say he actually was parenting, though the difference can be blurred amusingly by the harried existence of a college basketball coach. Anyway, it was closing in on 7 p.m. when Skerrys son, Owen, was working the iPad and in particular a specific app his mother installed to help him understand words and communicate. Owen, nearing his fifth birthday, is autistic. His vocabulary and language skills are limited. His intuition is not. Which was how Owen calculated the time of day and tapped into his sense of routine before tapping into technology to issue a pronouncement to a somewhat preoccupied dad. I want to take a bath, Pat Skerry was informed. Hes an unbelievable wizard on the iPad and some of these electronic gadgets, Skerry, the Towson basketball coach, said in a phone conversation Tuesday morning. Hes a heck of a lot smarter than I am with that stuff. If Skerry cant quite use a touch-screen as adeptly, he can use his position and his platform to advance awareness of the condition … Continue reading →

Rockville, MD (PRWEB) January 22, 2014 Opportunity Analyzer: Acute Ischemic Stroke - Opportunity Analysis and Forecasts to 2017 Given the Significant Unmet Needs in this Market, Several Opportunities Remain for Novel Therapies One opportunity includes thrombolytics that can be administered beyond nine hours. Although desmoteplase will have a potential extended therapeutic time window of nine hours, enabling a greater proportion of patients to be eligible for thrombolysis, there is ample opportunity for an effective and safe therapy that can be given after nine hours post-stroke onset. Acute Ischemic Stroke (AIS) patients are still awaiting approval of the first effective neuroprotective therapies, and given the lack of Phase III neuroprotective agents, GlobalData does not expect any neuroprotective agents to launch within the five-year forecast period. With the absence of such a product in the AIS treatment paradigm, an approved first-in-class neuroprotective agent is likely to gain rapid patient uptake. Novel neurorestorative therapies - although much progress has been made in the clinical management of stroke, for example in the form of next-generation thrombolytic agents such as desmoteplase, there are still limited treatment options to restore lost function once neuronal death has already occurred. To order this report: Opportunity Analyzer: Acute Ischemic … Continue reading →